Cargando…

New Antagonists of the Membrane Androgen Receptor OXER1 from the ZINC Natural Product Database

[Image: see text] OXER1 (oxoeicosanoid receptor 1) was deorphanized in 1993 and found to be the specific receptor for the arachidonic acid metabolite 5-oxo-ETE. Recently, we have reported that androgen binds to this receptor also, being a membrane androgen receptor, triggering a number of its membra...

Descripción completa

Detalles Bibliográficos
Autores principales: Panagiotopoulos, Athanasios A., Kalyvianaki, Konstantina, Notas, George, Pirintsos, Stergios A., Castanas, Elias, Kampa, Marilena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582029/
https://www.ncbi.nlm.nih.gov/pubmed/34778638
http://dx.doi.org/10.1021/acsomega.1c04027
Descripción
Sumario:[Image: see text] OXER1 (oxoeicosanoid receptor 1) was deorphanized in 1993 and found to be the specific receptor for the arachidonic acid metabolite 5-oxo-ETE. Recently, we have reported that androgen binds to this receptor also, being a membrane androgen receptor, triggering a number of its membrane-mediated actions (cell migration, apoptosis, cell proliferation, Ca(2+) movements). In addition, our previous work suggested that a number of natural monomeric and oligomeric polyphenols interact with OXER1, acting similar to testosterone. Here, we interrogated the natural product chemical space and identified nine polyphenolic molecules with interesting in silico pharmacological activities as putative OXER1 antagonists. The molecule with the best pharmacokinetic–pharmacodynamic properties (ZINC15959779) was purchased and tested on OXER1, in prostate cancer cell cultures. It showed that it has actions similar to those of testosterone in inhibiting cAMP, while it had no action in intracellular Ca(2+) mobilization or actin cytoskeleton rearrangement/migration. These results are discussed under the prism of structure–activity relationships and in silico models of the OXER1 binding groove. We suggest that these compounds, together with the previously reported (poly)phenolic compounds, can be lead structures for the exploration of the anti-inflammatory and antiproliferative effects of OXER1 antagonists.